Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

BACKGROUND: The peripheral blood eosinophil count prior to treatment has potential as a predictive biomarker for a beneficial clinical response to cancer immunotherapies. Therefore, the present study investigated the impact of the eosinophil count on overall survival (OS) in non‐small cell lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Eiji, Kondo, Kensuke, Okano, Yoshio, Ichihara, Seiya, Kunishige, Michihiro, Kadota, Naoki, Machida, Hisanori, Hatakeyama, Nobuo, Naruse, Keishi, Ogino, Hirokazu, Nokihara, Hiroshi, Shinohara, Tsutomu, Nishioka, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599974/
https://www.ncbi.nlm.nih.gov/pubmed/37669914
http://dx.doi.org/10.1111/1759-7714.15100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599974/
https://www.ncbi.nlm.nih.gov/pubmed/37669914
http://dx.doi.org/10.1111/1759-7714.15100

Ejemplares similares